• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month

    5/21/24 8:39:25 AM ET
    $BAX
    $RAPT
    $RENB
    $SAGE
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BAX alert in real time by email

    The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

    The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

    Here's the latest list of major oversold players in this sector, having an RSI near or below 30.

    Treace Medical Concepts, Inc. (NASDAQ:TMCI)

    • On May 7, Treace Medical Concepts reported first-quarter financial results and issued FY24 revenue guidance below estimates. John T. Treace, CEO and Founder of Treace, said, “Our first quarter revenue growth rate of 21% represents a strong start to 2024. Revenue performance in the quarter was driven by increased procedure kit volume from our expanding base of surgeons as well as increased adoption of our newer technologies, all supported by our dedicated, direct sales team.” The company's stock fell around 56% over the past month and has a 52-week low of $3.92 .
    • RSI Value: 29.74
    • TMCI Price Action: Shares of Treace Medical Concepts fell 1.2% to close at $4.94 on Monday.

    RAPT Therapeutics, Inc. (NASDAQ:RAPT)      

    • On May 9, RAPT Therapeutics announced that it has decided to close and unblind both its Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis (AD) and its Phase 2a trial of zelnecirnon in asthma. The company reported first-quarter net loss of 2024 was $30.5 million, compared to $29.3 million for the first quarter of 2023. The company's stock fell around 49% over the past month. It has a 52-week low of $3.9520.
    • RSI Value: 23.11
    • RAPT Price Action: Shares of RAPT Therapeutics fell 1% to close at $4.00 on Monday.

    Renovaro Inc. (NASDAQ:RENB)

    • On April 24, RenovaroCube announced plans to acquire 100% ownership of Cyclomics. The company's stock fell around 55% over the past month and has a 52-week low of $0.3930.
    • RSI Value: 22.49
    • RENB Price Action: Shares of Renovaro closed at $0.97 on Monday.

    Sage Therapeutics, Inc. (NASDAQ:SAGE)

    • On April 25, Sage Therapeutics posted a first-quarter GAAP loss of $1.80 per share. The company's shares lost around 11% over the past five days The company's 52-week low is $10.92.
    • RSI Value: 29.90
    • SAGE Price Action: Shares of Sage Therapeutics fell 4.4% to close at $11.18 on Monday.

    Baxter International Inc. (NYSE:BAX)

    • On May 2, Baxter International reported first-quarter adjusted EPS of 65 cents, up 10% Y/Y, beating the consensus of 61 cents. "Baxter's results in the first quarter reflect the company's solid operational performance, fueled by the benefits being realized from our ongoing strategic transformation initiatives, including our new operating model structure and continued strong execution across our integrated supply chain network," said José (Joe) E. Almeida, chair, president and chief executive officer. The company's shares fell around 13% over the past month. The company has a 52-week low of $31.01.
    • RSI Value: 26.30
    • BAX Price Action: Shares of Baxter International fell 0.7% to close at $35.02 on Monday.

    Read More: Jim Cramer Says This Materials Stock Is A ‘Great Spec,’ Plus He Recommends Buying Abercrombie & Fitch

    Get the next $BAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX
    $RAPT
    $RENB
    $SAGE

    CompanyDatePrice TargetRatingAnalyst
    RAPT Therapeutics Inc.
    $RAPT
    1/9/2026$95.00Overweight
    Piper Sandler
    Treace Medical Concepts Inc.
    $TMCI
    11/7/2025$5.00Neutral → Underweight
    Analyst
    Treace Medical Concepts Inc.
    $TMCI
    11/7/2025Buy → Neutral
    BTIG Research
    Baxter International Inc.
    $BAX
    10/31/2025Buy → Hold
    Argus
    RAPT Therapeutics Inc.
    $RAPT
    10/27/2025$70.00Buy
    Guggenheim
    RAPT Therapeutics Inc.
    $RAPT
    10/20/2025$55.00Neutral → Overweight
    Analyst
    RAPT Therapeutics Inc.
    $RAPT
    10/13/2025$35.00Overweight
    Barclays
    RAPT Therapeutics Inc.
    $RAPT
    9/26/2025$37.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $BAX
    $RAPT
    $RENB
    $SAGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings

    New system offers a standardized and simplified alternative to traditional handwritten line labeling that supports safer medication administration Solution aims to streamline nursing workflow, helping to save clinician time and reduce likelihood of medication errors related to IV line labeling inconsistencies Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and platforms, today debuted the IV Verify Line Labeling System, an automated solution, at the 2026 American Organization for Nursing Leadership Conference. The IV Verify system is designed to streamline nursing workflows, save clinician time and support safer medication administration at the bedsid

    3/30/26 8:30:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Host Annual Meeting of Stockholders in Virtual Format

    Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2026 Annual Meeting) in a virtual format on Tuesday, May 5, 2026 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2026 Annual Meeting. Online access to the 2026 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2026 Annual Meeting in person. The virtual format provides a safe, convenient and cost-effective experience to all stockholders and employees, regardless of location. Anyone who would like to attend the virtual 2026 Annual Meeting is encouraged to access the meeting in advance of the designated star

    3/25/26 4:30:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot

    Largest Single Investment from a Corporate Foundation Aims to Strengthen Healthcare Resilience by Advancing Therapy Animal Visits in U.S. Healthcare SettingsBELLEVUE, Wash. and DEERFIELD, Ill., March 25, 2026 /PRNewswire/ -- Pet Partners, the nation's leading organization dedicated to improving human health and well-being through therapy animal interactions, and the Baxter Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced a new partnership to expand access to therapy animal programs in healthcare settings across the country. The initiative will begin as a two-year pilot program in key regions, including Northern California, Up

    3/25/26 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $RAPT
    $RENB
    $SAGE
    SEC Filings

    View All

    SEC Form DEFA14A filed by Baxter International Inc.

    DEFA14A - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    3/23/26 8:52:56 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Baxter International Inc.

    DEF 14A - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    3/23/26 8:51:59 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    3/19/26 4:45:33 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $RAPT
    $RENB
    $SAGE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Treace John T. bought $524,064 worth of shares (60,000 units at $8.73), increasing direct ownership by 0.89% to 6,796,190 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/4/25 6:30:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. bought $265,630 worth of shares (50,000 units at $5.31), increasing direct ownership by 0.77% to 6,523,095 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    9/17/24 5:17:19 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Director Treace James T bought $501,035 worth of shares (84,000 units at $5.96), increasing direct ownership by 7% to 1,223,441 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    8/19/24 9:00:08 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $BAX
    $RAPT
    $RENB
    $SAGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on RAPT Therapeutics with a new price target

    Piper Sandler initiated coverage of RAPT Therapeutics with a rating of Overweight and set a new price target of $95.00

    1/9/26 9:07:04 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Treace Medical Concepts downgraded by Analyst with a new price target

    Analyst downgraded Treace Medical Concepts from Neutral to Underweight and set a new price target of $5.00

    11/7/25 8:29:21 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts downgraded by BTIG Research

    BTIG Research downgraded Treace Medical Concepts from Buy to Neutral

    11/7/25 8:29:10 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $BAX
    $RAPT
    $RENB
    $SAGE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

    For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

    8/8/23 9:34:19 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

    For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

    8/4/23 6:50:31 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BAX
    $RAPT
    $RENB
    $SAGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Hair Mark

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    4/3/26 9:00:04 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. covered exercise/tax liability with 7,083 shares, decreasing direct ownership by 0.10% to 7,004,550 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/11/26 9:00:04 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Hair Mark covered exercise/tax liability with 4,659 shares, decreasing direct ownership by 0.54% to 863,549 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/11/26 9:00:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $BAX
    $RAPT
    $RENB
    $SAGE
    Leadership Updates

    Live Leadership Updates

    View All

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care

    RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company's lead product candidate RPT904, is a novel, half-life extended monoclonal antibod

    6/23/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BAX
    $RAPT
    $RENB
    $SAGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/14/24 6:14:58 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Treace Medical Concepts Inc.

    SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/14/24 3:38:23 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

    SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

    11/14/24 1:22:39 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BAX
    $RAPT
    $RENB
    $SAGE
    Financials

    Live finance-specific insights

    View All

    Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

    PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% compared to the prior year.Reported fourth quarter 2025 net loss of $(9.4) million and adjusted EBITDA of $6.2 million in the fourth quarter 2025. Reported full-year 2025 net loss of $(59.0) million c

    2/27/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

    PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask qu

    2/12/26 5:13:32 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Baxter Reports Fourth-Quarter 2025 Results

    Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And

    2/12/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care